Targeted Oncology |
The Role of JAK2 Inhibition in Polycythemia Vera
Targeted Oncology Patients with high-risk PV should be treated with cytoreductive therapy in addition to standard management with aspirin and therapeutic phlebotomy. The first major clinical trial to evaluate the optimal management of PV, PVSG-01, randomized 431 ... |
from phlebotomy - Google News http://bit.ly/2LmJYMm
No comments:
Post a Comment